BIOtech Now e-newsletter

AUGUST 2010
Capital Infusion
The new Therapeutic Discovery Project Program offers small biotech firms a new funding source for continuing their work on groundbreaking medical therapies, points out Rep. Allyson Schwartz. Learn how companies can take advantage of this tax credit. Read more

Share:

HEALTH

Risk Factors
What’s the best approach for creating drug risk evaluation and mitigation strategies, or REMS? For starters, expand the participants in the process to include the public and health-care professionals. Read more

Share:

INDUSTRIAL

BROUGHT TO YOU BY

Favorable Future for Biofuels
Can the biofuels industry meet its investment goal of $200 billion over the next 10 years? Despite hurdles, the future for biorefineries appears positive, finds a new McKinsey survey. Read more

Share:

BUSINESS OF BIOTECH

Let's Make a Deal
Current biotechnology fundraising efforts focus more on partnering and dealmaking, rather than initial public offerings and venture capital funding. This is particularly true for Phase 2 and Phase 3 funding. Read more

Share:

FOOD & AG

BROUGHT TO YOU BY

Sowing Biotech Seeds
Biotech crops have enormous potential benefits, but recent rulings raise concerns about unfairly restricting development. Lawmakers take up the cause, calling for focus on science not politics. Read more

Share:

BIO NEWS

Time Tested

Gene patents lead to biotech breakthroughs. In the 30 years since the Supreme Court’s groundbreaking patent ruling in Diamond v. Chakrabarty, the biotech industry has blossomed. Read more

Share:

Share BIOtech NOW E-Newsletter on:

Visit:

PERSPECTIVE
Nothing to Fear But Fear Itself
Opponents of biotechnology stoke consumer distrust to drive up regulatory costs for biotech companies.
Read more

EVENTS

BIO India International Partnering Conference
Sept. 21-22
Hyderabad, India

Livestock Biotech Summit
Sept. 28-30
Sioux Falls, S.D.

9th Annual BIO Investor Forum
Oct. 5–6
San Francisco

RECENT LETTERS

Genetic Testing Registry: NIH lays out a plan for a Genetic Test Registry that can provide the public and regulators vital information.

BioShield Special Reserve Fund: Senate rightly rejects House’s proposed $2 billion cut from appropriations for the BioShield SRF.

NCAs for New Therapies: A national coverage analysis of a recently approved therapy could establish a precedent that affects Medicare patients’ access to new medicines.